BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF from Chinese biotech
read at Endpoints ↗DealPositive
BeOne Medicines, formerly known as BeiGene, announced a licensing agreement with a Chinese biotechnology firm to obtain rights to an experimental trispecific antibody.
The antibody is engineered to block the PD-1, CTLA-4 and VEGF pathways at the same time, a strategy intended to boost anti‑cancer efficacy beyond single‑target drugs.
The arrangement includes an option for BeOne to further develop and eventually commercialize the candidate, positioning the company to compete in the expanding VEGF‑targeted therapy market.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF”
read at Endpoints ↗81 words · retrieved Apr 28
comments(0)
5-min edit window · permanent after that